Exclusive special offer and discount title banner vector image

ASIA-PACIFIC MALE INFERTILITY MARKET FORECAST 2023-2032

SCOPE OF THE REPORT

Asia-Pacific Male Infertility Market by Test Type (DNA Fragmentation Technique, Oxidative Stress Analysis, Microscopic Examination, Sperm Agglutination, Computer-assisted Semen Analysis, Sperm Penetration Assay, Other Test Types) Market by Treatment (Assisted Reproductive Technology and Surgery, Medications) by Geography


MARKET OVERVIEW

The Asia-Pacific male infertility market is estimated to generate $1451.87 million by 2032, surging with a 5.06% CAGR during the forecasted period of 2023 and 2032.

Several key factors are expected to contribute to the growth of the male infertility market in the Asia-Pacific region. These factors include consumer disposable income, growing awareness regarding male infertility, technological advancements, and various collaborations and strategic agreements within the industry. Furthermore, the region has recently witnessed the establishment of fertility clinics, which are anticipated to further enhance market growth throughout the forecast period.

To Know More About This Report, Request a Free Sample Copy

The Asia-Pacific male infertility market growth assessment includes the analysis of Australia & New Zealand, South Korea, Thailand, Vietnam, Japan, China, India,  Indonesia, and Rest of Asia-Pacific. The male infertility market in China is poised for rapid expansion due to various factors. The increased prevalence of diseases such as diabetes, genetic abnormalities, and infections like chlamydia, gonorrhea, mumps, and HIV is anticipated to drive market growth. China’s persistent rise in male infertility cases and the widespread adoption of Assisted Reproductive Technology (ART) will further expand market growth. 

However, the increasing prevalence of diabetes, projected to reach 9.7% among Chinese adults aged 20-79 by 2030, may negatively impact fertility rates. Furthermore, the brucella bacterial infection outbreak in China, which causes male infertility, is also favorably influencing the market. These factors collectively indicate a promising growth trajectory for the male infertility market in China during the forecast period.

The male infertility market in Japan is poised for growth in the forecast period due to several key factors. One contributing factor is the high rate of smoking and unhealthy lifestyle habits prevalent in the population. According to the World Health Organization Framework Convention on Tobacco Control, Japan’s smoking rate was 18.2% in 2020, with 30.1% of Japanese men being smokers. This historically high percentage of smokers can adversely affect sperm counts and increase the risk of erectile dysfunction among men. 

Consequently, the demand for male infertility treatments is expected to rise, driving market expansion. Additionally, the adoption of assisted reproductive technologies, the availability of reimbursements and insurance for couples seeking such treatments, and other factors will also contribute to the growth of the male infertility market in Japan.

The Asia-Pacific male infertility market segmentation entails the evaluation by test type and treatment. Market by test type covers microscopic examination, DNA fragmentation technique, sperm agglutination, oxidative stress analysis, computer-assisted semen analysis, sperm penetration assay, and other test types.

The DNA fragmentation technique serves as an effective means to detect male infertility, where changes in nucleotide composition or physical breaks occur in one or both sperm chromosomes. Studies indicate that infertile males are more prone to sperm DNA damage, leading to unfavorable reproductive outcomes. 

Consequently, the DNA fragmentation approach holds promise as a novel method for fertility evaluation. In specific clinical scenarios, sperm DNA fragmentation (SDF) tests are used as complementary assessments alongside traditional semen analysis. With its wide acceptance and diagnostic capabilities in assessing sperm DNA integrity, the DNA fragmentation technique is anticipated to witness robust growth in the coming years. 

Factors such as clinical diseases, environmental exposures, lifestyle risks, and innovations in testing methods contribute to the market’s expansion. Notably, Legacy, an online male reproductive clinic, introduced the first consumer-friendly at-home sperm DNA fragmentation (SDF) analysis in 2021, further enhancing market potential.

Key players operating in the Asia-Pacific male infertility market include Zydus Lifesciences Ltd (Cadila Healthcare Ltd), Bayer Group, etc.

Zydus Lifesciences Limited (formerly Cadila Healthcare Limited) is a leading Indian multinational pharmaceutical company. Specializing in generics, it innovates across NCEs, biosimilars, vaccines, and niche technologies. With global operations and 35 manufacturing facilities, the company is headquartered in Gujarat, India.

Zydus offers cost-effective and high-quality pharmaceutical products, including Paternia XT Tablet, a nutritional supplement for male fertility enhancement.

REPORT SYNOPSIS

REPORT SCOPEDETAILS
Market Forecast Years2023-2032
Base Year2022
Market Historical Years2018-2022
Forecast UnitsRevenue ($ Million)
Segments Analyzed
Test Type and Treatment
Countries AnalyzedChina, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia Pacific
Companies AnalyzedAdvaCare Pharma USA, Andrology Solutions, Aytu BioPharma, Bayer Group, Caerus Biotech, CinnaGen Co, EMD Serono Inc (Merck Serono), Endo International PLC, Halotech DNA, Laboratory Corporation of America Holdings, Sanofi, SCSA Diagnostics, Theramex, Vitrolife, Zydus Lifesciences Ltd (Cadila Healthcare Ltd)

TABLE OF CONTENT

  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. METHODOLOGY
    3. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
    3. SCOPE OF STUDY
    4. CRISIS SCENARIO ANALYSIS
    5. MAJOR MARKET FINDINGS
      1. PRODUCT DEVELOPMENTS AND LAUNCHES BY MARKET PLAYERS PROMOTE MARKET GROWTH
      2. PREVALENCE OF DIABETES AND CANCER
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. SURGING INFERTILITY INCIDENCES 
      2. ASSISTED REPRODUCTIVE TECHNOLOGY ADOPTION
      3. TECHNOLOGICAL ADVANCEMENTS
    2. KEY RESTRAINTS
      1. HIGH TREATMENT COSTS
  4. KEY ANALYTICS
    1. KEY MARKET TRENDS
    2. PORTER’S FIVE FORCES ANALYSIS
      1. BUYERS POWER
      2. SUPPLIERS POWER
      3. SUBSTITUTION
      4. NEW ENTRANTS
      5. INDUSTRY RIVALRY
    3. GROWTH PROSPECT MAPPING
    4. MARKET MATURITY ANALYSIS
    5. MARKET CONCENTRATION ANALYSIS
  5. MARKET BY TEST TYPE
    1. DNA FRAGMENTATION TECHNIQUE
    2. OXIDATIVE STRESS ANALYSIS
    3. MICROSCOPIC EXAMINATION
    4. SPERM AGGLUTINATION
    5. COMPUTER-ASSISTED SEMEN ANALYSIS
    6. SPERM PENETRATION ASSAY
    7. OTHER TEST TYPES
  6. MARKET BY TREATMENT
    1. ASSISTED REPRODUCTIVE TECHNOLOGY AND SURGERY
    2. MEDICATIONS
  7. GEOGRAPHICAL ANALYSIS
    1. ASIA-PACIFIC
      1. MARKET SIZE & ESTIMATES
      2. ASIA-PACIFIC MALE INFERTILITY MARKET DRIVERS
      3. ASIA-PACIFIC MALE INFERTILITY MARKET CHALLENGES
      4. KEY PLAYERS IN ASIA-PACIFIC MALE INFERTILITY MARKET
      5. COUNTRY ANALYSIS
        1. CHINA
          1. CHINA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
        2. JAPAN
          1. JAPAN MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
        3. INDIA
          1. INDIA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
        4. SOUTH KOREA
          1. SOUTH KOREA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
        5. INDONESIA
          1. INDONESIA MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
        6. THAILAND
          1. THAILAND MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
        7. VIETNAM
          1. VIETNAM MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
        8. AUSTRALIA & NEW ZEALAND
          1. AUSTRALIA & NEW ZEALAND MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
        9. REST OF ASIA-PACIFIC
          1. REST OF ASIA-PACIFIC MALE INFERTILITY MARKET SIZE & OPPORTUNITIES
  8. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGERS & ACQUISITIONS
      2. PRODUCT LAUNCHES & DEVELOPMENTS
      3. PARTNERSHIPS & AGREEMENTS
      4. BUSINESS EXPANSIONS
    2. COMPANY PROFILES
      1. ADVACARE PHARMA USA
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
      2. ANDROLOGY SOLUTIONS
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
      3. AYTU BIOPHARMA
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      4. BAYER GROUP
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      5. CAERUS BIOTECH
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
      6. CINNAGEN CO
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      7. EMD SERONO INC (MERCK SERONO)
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      8. ENDO INTERNATIONAL PLC
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      9. HALOTECH DNA
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
      10. LABORATORY CORPORATION OF AMERICA HOLDINGS
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      11. SANOFI
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      12. SCSA DIAGNOSTICS
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
      13. THERAMEX
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
      14. VITROLIFE
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES
      15. ZYDUS LIFESCIENCES LTD (CADILA HEALTHCARE LTD)
        1. COMPANY OVERVIEW
        2. PRODUCTS / SERVICES LIST
        3. STRENGTHS & CHALLENGES

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – MALE INFERTILITY

TABLE 2: ASIA-PACIFIC MALE INFERTILITY MARKET, BY TEST TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 3: ASIA-PACIFIC MALE INFERTILITY MARKET, BY TEST TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 4: ASIA-PACIFIC MALE INFERTILITY MARKET, BY TREATMENT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 5: ASIA-PACIFIC TREATMENT MARKET, BY TREATMENT, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 6: ASIA-PACIFIC MALE INFERTILITY MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)

TABLE 7: ASIA-PACIFIC MALE INFERTILITY MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)

TABLE 8: KEY PLAYERS OPERATING IN ASIA-PACIFIC MALE INFERTILITY MARKET

TABLE 9: LIST OF MERGERS & ACQUISITIONS

TABLE 10: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 11: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 12: LIST OF BUSINESS EXPANSIONS

LIST OF FIGURES 

FIGURE 1: PORTER’S FIVE FORCES ANALYSIS

FIGURE 2: GROWTH PROSPECT MAPPING 

FIGURE 3: MARKET MATURITY ANALYSIS

FIGURE 4: MARKET CONCENTRATION ANALYSIS

FIGURE 5: ASIA-PACIFIC MALE INFERTILITY MARKET, GROWTH POTENTIAL, BY TEST TYPE, IN 2022

FIGURE 6: ASIA-PACIFIC MALE INFERTILITY MARKET, BY DNA FRAGMENTATION TECHNIQUE, 2023-2032 (IN $ MILLION)

FIGURE 7: ASIA-PACIFIC MALE INFERTILITY MARKET, BY OXIDATIVE STRESS ANALYSIS, 2023-2032 (IN $ MILLION)

FIGURE 8: ASIA-PACIFIC MALE INFERTILITY MARKET, BY MICROSCOPIC EXAMINATION, 2023-2032 (IN $ MILLION)

FIGURE 9: ASIA-PACIFIC MALE INFERTILITY MARKET, BY SPERM AGGLUTINATION, 2023-2032 (IN $ MILLION)

FIGURE 10: ASIA-PACIFIC MALE INFERTILITY MARKET, BY COMPUTER-ASSISTED SEMEN ANALYSIS, 2023-2032 (IN $ MILLION)

FIGURE 11: ASIA-PACIFIC MALE INFERTILITY MARKET, BY SPERM PENETRATION ASSAY, 2023-2032 (IN $ MILLION)

FIGURE 12: ASIA-PACIFIC MALE INFERTILITY MARKET, BY OTHER TEST TYPES, 2023-2032 (IN $ MILLION)

FIGURE 13: ASIA-PACIFIC TREATMENT MARKET, GROWTH POTENTIAL, BY TREATMENT, IN 2022

FIGURE 14: ASIA-PACIFIC MALE INFERTILITY MARKET, BY ASSISTED REPRODUCTIVE TECHNOLOGY AND SURGERY, 2023-2032 (IN $ MILLION)

FIGURE 15: ASIA-PACIFIC MALE INFERTILITY MARKET, BY MEDICATIONS, 2023-2032 (IN $ MILLION)

FIGURE 16: ASIA-PACIFIC MALE INFERTILITY MARKET, COUNTRY OUTLOOK, 2022 & 2032 (IN%)

FIGURE 17: CHINA MALE INFERTILITY MARKET, 2023-2032 (IN $ MILLION)

FIGURE 18: JAPAN MALE INFERTILITY MARKET, 2023-2032 (IN $ MILLION)

FIGURE 19: INDIA MALE INFERTILITY MARKET, 2023-2032 (IN $ MILLION)

FIGURE 20: SOUTH KOREA MALE INFERTILITY MARKET, 2023-2032 (IN $ MILLION)

FIGURE 21: INDONESIA MALE INFERTILITY MARKET, 2023-2032 (IN $ MILLION)

FIGURE 22: THAILAND MALE INFERTILITY MARKET, 2023-2032 (IN $ MILLION)

FIGURE 23: VIETNAM MALE INFERTILITY MARKET, 2023-2032 (IN $ MILLION)

FIGURE 24: AUSTRALIA & NEW ZEALAND MALE INFERTILITY MARKET, 2023-2032 (IN $ MILLION)

FIGURE 25: REST OF ASIA-PACIFIC MALE INFERTILITY MARKET, 2023-2032 (IN $ MILLION)

FAQ’s